A new study has found that older adults who received a high-dose influenza vaccine had a lower risk of developing Alzheimer’s disease than those who received a standard-dose flu shot. The research, published in the medical journal Neurology on April 28, 2026, analysed health records from nearly 165,000 people aged 65 and older in the United States. Researchers found that the association was strongest during the first two years following vaccination, with women appearing to experience a more sustained reduction in risk.
The findings add to growing scientific interest in whether routine vaccinations could have benefits beyond protecting people against infectious diseases. However, researchers caution that the study does not prove that high-dose flu vaccines prevent Alzheimer’s disease. It was based on observational healthcare data rather than a randomized clinical trial, meaning other differences between the participants could have influenced the results. The research therefore provides evidence of an association, not proof of a preventive treatment for dementia.
Study Examined Nearly 165,000 Older Adults
The research was conducted by scientists associated with the University of Texas Health Science Center at Houston (UTHealth Houston).
Researchers analysed US healthcare insurance claims involving 164,797 adults aged 65 and older who received influenza vaccinations.
The participants were divided into two groups:
- High-dose vaccine group: 120,775 people received a high-dose influenza vaccine.
- Standard-dose vaccine group: 44,022 people received a conventional influenza vaccine.
The average age was approximately 74 years in the high-dose group and 73 years in the standard-dose group.
Researchers followed participants for up to three years after vaccination, examining healthcare records to identify new Alzheimer’s diagnoses.
Rather than comparing vaccinated people with an entirely unvaccinated population, the researchers compared two groups who had both received flu vaccines. This approach helped reduce some differences associated with vaccination behaviour and healthcare access.
The study used statistical methods designed to make the comparison more reliable, including techniques that account for differences between participants over time.
High-Dose Flu Vaccine Linked to Lower Alzheimer’s Risk
The study found that people who received high-dose influenza vaccines had a significantly lower risk of developing Alzheimer’s dementia than those who received standard-dose vaccines.
The association was statistically significant during the first 25 months following vaccination in the main analysis.
Researchers estimated that approximately 185 people would need to receive the high-dose vaccine instead of the standard-dose version to correspond to one fewer Alzheimer’s diagnosis over the period when the difference was observed.
This measure is known as the number needed to treat (NNT). It does not mean that exactly one Alzheimer’s case will be prevented every time 185 people receive the vaccine. It is an estimate based on the observed difference between the two groups.
The findings suggest that the higher-dose vaccine may be associated with additional benefits for brain health, although further research is needed to determine whether the relationship is causal.
Women Appeared to Experience a Stronger Association
Researchers also examined whether the relationship differed between men and women.
The results suggested that women who received high-dose flu vaccines experienced a statistically significant reduction in Alzheimer’s risk over a longer period than men in the study’s analyses.
Among women, the association remained statistically significant during the first 13 months in the per-protocol analysis. Among men, the significant association appeared later, during months 17 to 24 in the intention-to-treat analysis.
The researchers estimated a number needed to treat of approximately 417 for women at the point of the strongest observed difference in that analysis.
These results suggest that sex may influence the relationship between influenza vaccination and Alzheimer’s risk.
However, the study does not establish why the association appeared different between men and women. Researchers say additional investigations are needed to understand the biological and clinical factors involved.
Why Could a Flu Vaccine Affect Alzheimer’s Risk?
Scientists are increasingly investigating the relationship between infections, immune-system activity and neurodegenerative diseases.
Alzheimer’s disease involves progressive changes in the brain, including the accumulation of abnormal proteins and damage to nerve cells. Inflammation is also believed to play a role in the disease’s development and progression.
One hypothesis is that preventing influenza infections may reduce inflammatory activity that could otherwise affect the brain.
Vaccination activates the immune system to recognise and respond to a particular virus. Researchers are investigating whether this immune response could also influence inflammatory processes beyond the immediate prevention of infection.
Another possibility is that high-dose vaccines produce a stronger or more sustained immune response in older adults.
However, these explanations remain hypotheses. The study did not directly establish the biological mechanism responsible for the observed difference in Alzheimer’s diagnoses.
The researchers said further work is necessary to determine whether the association reflects protection against infections, changes in immune activity or other factors.
What Makes High-Dose Flu Vaccines Different?
High-dose influenza vaccines are designed particularly for older adults, whose immune systems may not respond as strongly to conventional vaccines.
The high-dose formulation contains four times the amount of influenza antigen found in a standard-dose vaccine.
Antigens are components that help the immune system recognise a virus and develop an immune response.
As people age, immune-system function can decline, a process known as immunosenescence. This can make older adults more vulnerable to influenza complications and reduce their response to standard vaccinations.
Higher-dose vaccines are designed to produce a stronger immune response in this age group.
In the United States, high-dose influenza vaccines are among the preferred options for adults aged 65 and older when available.
The latest study raises the possibility that the stronger immune response could be associated with additional neurological benefits, although Alzheimer’s prevention has not been established as a reason for receiving the vaccine.
Important Limitations: The Study Does Not Prove Prevention
Despite the encouraging findings, the research has several limitations.
First, it was an observational study using healthcare claims rather than a randomized controlled trial. Researchers did not randomly assign participants to receive high-dose or standard-dose vaccines.
This means other factors could have influenced the results. For example, people receiving high-dose vaccines may have had better access to healthcare, different health habits or other characteristics that affected their risk of developing Alzheimer’s disease.
Second, the follow-up period lasted no longer than three years. Alzheimer’s disease can develop over many years, and changes in the brain may begin long before symptoms become noticeable.
Third, researchers identified Alzheimer’s diagnoses through healthcare records rather than conducting detailed clinical examinations and biomarker testing for every participant.
The study also found that the apparent difference was less consistent when certain dementia-related diagnostic codes were excluded. This raises questions about how accurately the findings represent Alzheimer’s disease specifically rather than dementia more broadly.
The authors said further research involving longer follow-up periods and more precise clinical diagnoses will be necessary.
Should Older Adults Get High-Dose Flu Shots to Prevent Alzheimer’s?
The findings should not be interpreted as proof that people should receive high-dose flu vaccines specifically to prevent Alzheimer’s disease.
The established purpose of influenza vaccination is to reduce the risk of influenza infection and its complications.
For older adults, influenza can lead to serious illness, hospitalization and death. Vaccination remains an important preventive measure.
The study provides an additional research question about whether stronger influenza vaccines might also influence long-term brain health.
However, the evidence is not sufficient to establish high-dose vaccination as an Alzheimer’s prevention strategy.
People should follow vaccination recommendations applicable to their age, health conditions and country, and discuss the appropriate vaccine with a healthcare professional.
The Bigger Picture
The findings contribute to a growing body of research examining whether vaccinations could influence the risk of dementia. Earlier observational studies have also reported associations between influenza vaccination and lower Alzheimer’s risk. Researchers are particularly interested in whether reducing infections and modifying immune-system activity could affect the processes involved in neurodegenerative diseases.
However, the distinction between association and causation remains important. The latest research does not demonstrate that a high-dose flu vaccine prevents Alzheimer’s, nor does it establish that the vaccine changes the underlying development of the disease. Larger studies, longer follow-up periods and randomized clinical trials could help determine whether the observed relationship represents a genuine protective effect.
Looking Ahead
Researchers will need to investigate whether the association can be replicated in other populations and whether the apparent differences between men and women remain consistent. Future studies could also examine whether repeated high-dose vaccinations produce sustained differences in Alzheimer’s risk and whether specific immune responses explain the results. More reliable clinical diagnoses and longer observation periods will be particularly important because Alzheimer’s can develop over decades.
For now, the study offers an interesting finding rather than a new treatment recommendation. High-dose influenza vaccines already have an established role in protecting older adults against flu-related complications in countries where they are recommended. Whether they can also help reduce Alzheimer’s risk remains an open scientific question.
Get the day’s top stories in your inbox
One concise email. No spam, unsubscribe anytime.



